Truist Financial Corp. closed 5.45% below its 52-week high of $49.06, which the company reached on November 25th.

In a report released today, Barry Jonas from Truist Financial maintained a Buy rating on DraftKings (DKNG – Research Report). The company’s ...

Truist Financial analyst Joel Fishbein reiterated a Buy rating on Palo Alto Networks (PANW – Research Report) today. The company’s shares ...

We recently compiled a list of the Top 14 AI Stocks on Wall Street: News and Analyst Ratings. In this article, we are going ...

We recently compiled a list of the 10 Best Bank Dividend Stocks To Buy Right Now. In this article, we are going to take a ...

Confluent (NASDAQ:CFLT – Get Free Report) had its price target boosted by equities researchers at Truist Financial from ...

Discover Truist’s checking account features, fees, and benefits in our comprehensive review. Learn how to maximize perks and ...

Truist Financial Corporation ( NYSE: TFC) UBS Financial Services Conference February 11, 2025 1:00 PM ET Buddy, as I say, no rest for the weary. But obviously my energy levels are back up, because we ...

On Tuesday, March 25, the South Carolina Gamecocks will take on the UNC Tar Heels for the ninth straight time at the home of ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target hoisted by equities researchers at Truist Financial from $100.00 to $120.00 in a report issued on Wednesday,Benzinga reports.

Pacira BioSciences (PCRX) stock was upgraded by Truist based on a potential settlement to its patent dispute with eVenus Pharmaceutical. Read more here.